RedHill Biopharma develops medicines for gastrointestinal and infectious diseases, promoting drugs like Talicia for H. pylori infections and Aemcolo for travelers’ diarrhea. Their late-stage programs include RHB-204, opaganib, RHB-107, RHB-104, and RHB-102.
RDHL has been in the news recently: GC Biopharma's anthrax vaccine, BARYTHRAX, was approved by Korea's MFDS on April 8, 2025, marking it as the country's 39th novel drug. Additionally, Prezent has appointed Janet Dorling to its Board of Directors to improve its AI presentation platform for the biopharmaceutical sector.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
